Daniel V.T. Catenacci
Impact in
- Oncology top 0.5%
- Cancer Immunotherapy and Biomarkers
- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Treatments and Studies
- Pulmonary and Respiratory Medicine top 0.5%
- Gastric Cancer Management and Outcomes
- Lung Cancer Treatments and Mutations
Papers in
-
- Gastric Cancer Management and Outcomes 57
- Lung Cancer Treatments and Mutations 11
- Oncology 46
- Cancer Immunotherapy and Biomarkers 19
- Pancreatic and Hepatic Oncology Research 9
- HER2/EGFR in Cancer Research 9
- Co-authors
- Jeffrey S. Ross (6 shared papers)Siraj Mahamed Ali (6 shared papers)Do‐Youn Oh (7 shared papers)Hyun Cheol Chung (9 shared papers)Mitesh J. Borad (7 shared papers)Ghassan K. Abou-Alfa (7 shared papers)Eric Van Cutsem (13 shared papers)Adrian Gerard Murphy (7 shared papers)
- Journals
- Annals of Oncology (27 papers)Clinical Cancer Research (9 papers)The Lancet Oncology (8 papers)The Oncologist (8 papers)Journal of Clinical Oncology (6 papers)
- Partner nations
- United StatesSouth KoreaJapan
In The Last Decade
Daniel V.T. Catenacci
132 papers receiving 13.1k citations
Daniel V.T. Catenacci's Hit Papers
Peers
Comparison fields: 5 of 103
- Oncology 4.6k
- Pulmonary and Respiratory Medicine 3.3k
- Cancer Research 1.4k
- Surgery 3.6k
- Hepatology 288
Countries citing papers authored by Daniel V.T. Catenacci
This map shows the geographic impact of Daniel V.T. Catenacci's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel V.T. Catenacci with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel V.T. Catenacci more than expected).
Fields of papers citing papers by Daniel V.T. Catenacci
This network shows the impact of papers produced by Daniel V.T. Catenacci. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel V.T. Catenacci. The network helps show where Daniel V.T. Catenacci may publish in the future.
Co-authors
The 25 scholars most cited alongside Daniel V.T. Catenacci, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 132 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer Hit paper breakdown → | 2018 | 1485 |
| 2 | Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study Hit paper breakdown → | 2020 | 1235 |
| 3 | Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial Hit paper breakdown → | 2016 | 936 |
| 4 | Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study Hit paper breakdown → | 2020 | 838 |
| 5 | Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer Hit paper breakdown → | 2019 | 501 |
| 6 | 2015 | 484 | |
| 7 | New Routes to Targeted Therapy of Intrahepatic Cholangiocarcinomas Revealed by Next-Generation Sequencing Hit paper breakdown → | 2014 | 399 |
| 8 | Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation Hit paper breakdown → | 2021 | 384 |
| 9 | Biliary cancer: Utility of next‐generation sequencing for clinical management Hit paper breakdown → | 2016 | 342 |
| 10 | Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability–High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials Hit paper breakdown → | 2021 | 334 |
| 11 | Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2017 | 303 |
| 12 | 2015 | 270 | |
| 13 | 2017 | 253 | |
| 14 | Treatment of Locally Advanced Esophageal Carcinoma: ASCO Guideline Hit paper breakdown → | 2020 | 226 |
| 15 | 2018 | 218 | |
| 16 | 2019 | 208 | |
| 17 | 2015 | 201 | |
| 18 | 2019 | 199 | |
| 19 | 2019 | 185 | |
| 20 | 2013 | 183 |
About Daniel V.T. Catenacci
Daniel V.T. Catenacci is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Surgery, Cancer Research and Pathology and Forensic Medicine, having authored 132 papers that have together received 13.3k indexed citations. Recurring topics across this work include Gastric Cancer Management and Outcomes (57 papers), Cancer Immunotherapy and Biomarkers (19 papers), Esophageal Cancer Research and Treatment (16 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (15 papers), Cancer Genomics and Diagnostics (14 papers), Lung Cancer Treatments and Mutations (11 papers), Pancreatic and Hepatic Oncology Research (9 papers) and HER2/EGFR in Cancer Research (9 papers). The work is most often cited by research in Oncology (4.6k citations), Pulmonary and Respiratory Medicine (3.3k citations), Cancer Research (1.4k citations), Surgery (3.6k citations) and Hepatology (288 citations). Daniel V.T. Catenacci has collaborated with scholars based in United States, South Korea and Japan. Frequent co-authors include Jeffrey S. Ross, Siraj Mahamed Ali, Do‐Youn Oh, Hyun Cheol Chung, Mitesh J. Borad, Ghassan K. Abou-Alfa, Eric Van Cutsem, Adrian Gerard Murphy, Steven Brad Maron and Christine Francis Lihou. Their work appears in journals such as Annals of Oncology, Clinical Cancer Research, The Lancet Oncology, The Oncologist and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.